Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's lead cell therapy candidate, deramiocel, and its FDA approval process [1][2]. Group 1: Allegations and Impact - Shareholders who purchased shares of Capricor during the class period from October 9, 2024, to July 10, 2025, are encouraged to contact the firm for possible lead plaintiff appointment [1]. - The complaint alleges that Capricor provided investors with misleading information about deramiocel's potential FDA approval while concealing adverse facts from its Phase 2 HOPE-2 trial [1]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the Biologics License Application (BLA) due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [1]. Group 2: Next Steps for Shareholders - Shareholders are advised to register for the class action by September 15, 2025, to participate in the case without any cost or obligation [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims is from April 29, 2025, to June 23, 2025 [2]. - The complaint claims that Hims engaged in deceptive promotion and selling of knockoff versions of Wegovy, risking patient safety [2]. - There is a substantial risk that the collaboration with Novo Nordisk could be terminated due to these practices [2]. - The positive statements made by the defendants regarding the company's business and operations were materially misleading and lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased HIMS shares during the class period are encouraged to register for potential lead plaintiff appointment [1][3]. - The deadline for shareholders to register is August 25, 2025, and there is no cost or obligation to participate [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CTO Realty Growth, Inc. (NYSE: CTO). https://securitiesclasslaw.com/securities/cto-realty-growth-inc-loss-submission-form/?id=161246&from=4 CONTACT: CLASS PERIOD: February 18, 2021 to June 24, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) CTO's dividends were less sustainable than ...

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Flywire Corporation (NASDAQ: FLYW). CLASS PERIOD: February 28, 2024 to February 25, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the strength and sustainability of Flywire's revenue growth was overstated; (ii) the negative impact that permit- and visa-related restrictions were hav ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1]. Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS, which is a prescription gene therapy for Duchenne muscular dystrophy [1]. - Specific allegations include that ELEVIDYS posed significant safety risks to patients, trial protocols failed to detect severe side effects, and the severity of adverse events would lead to a halt in recruitment and dosing in trials, attracting regulatory scrutiny [1]. Class Action Details - Shareholders who purchased shares of SRPT during the specified class period are encouraged to register for the class action, with a deadline of August 25, 2025, to seek lead plaintiff status [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case, with no cost or obligation to participate [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [3].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its integration with the Food Safety Division of 3M Company, which misled investors about the progress of the integration [3]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from January 5, 2023, to June 3, 2025 [3]. - Defendants allegedly downplayed inefficiencies arising from the integration and assured investors of their commitment to resolving these issues quickly [3]. - Shareholders are encouraged to register for the class action by the deadline of September 16, 2025, to potentially become lead plaintiffs [4]. Group 2: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

https://securitiesclasslaw.com/securities/neogen-corporation-loss-submission-form/?id=160431&from=4 CLASS PERIOD: January 5, 2023 to June 3, 2025 ALLEGATIONS: According to the filed complaint, defendants issued a series of materially false and misleading statements which led investors to believe that the integration with the Food Safety Division of the 3M Company was progressing much better than it actually was. In addition, even when the Company was forced to reveal that certain "inefficiencies" arose as a ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit due to alleged misleading statements and undisclosed issues affecting the company's performance during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from November 7, 2024, to July 8, 2025, RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [1]. - It is claimed that the defendants overstated the demand for RxSight's products [1]. - As a result of these issues, RxSight is unlikely to meet its previously issued financial guidance for fiscal year 2025 [1]. - The positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [1]. Class Action Details - Shareholders who purchased shares of RXST during the specified class period are encouraged to register for the class action, with a deadline of September 22, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sable Offshore Corp. (NYSE: SOC). Shareholders who purchased shares of SOC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sable-offshore-corp-loss-submission-form/?id=160437&from=4 CLASS PERIOD: This lawsuit ...

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ALT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is October 6, 2025. There is no cost or obligation to you to participate in this case. Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible ...